Detalhe da pesquisa
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-36001711
2.
Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants.
Ann Neurol
; 93(2): 285-296, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36093738
3.
Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.
Brain
; 146(2): 645-656, 2023 02 13.
Artigo
Inglês
| MEDLINE | ID: mdl-35253861
4.
Specific hypomethylation programs underpin B cell activation in early multiple sclerosis.
Proc Natl Acad Sci U S A
; 118(51)2021 12 21.
Artigo
Inglês
| MEDLINE | ID: mdl-34911760
5.
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
Ann Neurol
; 91(2): 268-281, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34878197
6.
Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.
AJR Am J Roentgenol
; 220(1): 115-125, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35975888
7.
A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis.
Proc Natl Acad Sci U S A
; 117(37): 22932-22943, 2020 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32859762
8.
New drugs for multiple sclerosis: new treatment algorithms.
Curr Opin Neurol
; 35(3): 262-270, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35674067
9.
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Ann Neurol
; 89(5): 895-910, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33724534
10.
Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis.
Brain
; 144(2): 450-461, 2021 03 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33374005
11.
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Eur J Neurol
; 28(11): 3722-3730, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34292643
12.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Lancet
; 394(10206): 1352-1363, 2019 10 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31495497
13.
Telomere Length Is Associated with Disability Progression in Multiple Sclerosis.
Ann Neurol
; 86(5): 671-682, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31486104
14.
Silent progression in disease activity-free relapsing multiple sclerosis.
Ann Neurol
; 85(5): 653-666, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30851128
15.
Herpes viral infection and the multiple sclerosis prodrome: is HHV-6A infection a second hit?
Brain
; 147(1): 7-9, 2024 01 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38109777
16.
Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.
Proc Natl Acad Sci U S A
; 114(40): 10713-10718, 2017 10 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28893978
17.
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.
Curr Opin Neurol
; 32(3): 365-377, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30985372
18.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Lancet
; 391(10127): 1263-1273, 2018 03 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29576505
19.
Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
Ann Neurol
; 84(1): 51-63, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29908077
20.
Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury.
Brain
; 141(1): 85-98, 2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29244098